Drug utilization research at the individual level as the main concept of pharmacoepidemiology
https://doi.org/10.37489/2782-3784-myrwd-33
EDN: FGOIEC
Abstract
Pharmacoepidemiological studies are necessary to improve the system of rational use of drugs and to identify the most problematic areas. Such studies make it possible to evaluate not only quantitative indicators of consumption but also indicators such as patient adherence, frequency of cases of polypharmacy, and drug abuse.
About the Authors
S. M. Mukhina
Pavlov First Saint Petersburg State Medical Unversity
Russian Federation
Competing Interests:
Russian Federation
Mukhina Sofia M. — Resident of the department of Clinical Pharmacology and Evidence-Based Medicine
St. Petersburg
Competing Interests:
The authors declare no conflict of interest.
M. I. Baranova
Pavlov First Saint Petersburg State Medical Unversity
Russian Federation
Competing Interests:
Russian Federation
Baranova Marina I. — assistant of the department of Clinical Pharmacology and Evidence-Based Medicine
RSCI AuthorID: 782722
St. Petersburg
Competing Interests:
The authors declare no conflict of interest.
Yu. M. Gomon
Pavlov First Saint Petersburg State Medical Unversity
Russian Federation
Competing Interests:
Russian Federation
Gomon Yulia M. — doctor of medical science, professor of the department of Clinical Pharmacology and Evidence-Based Medicine
RSCI AuthorID: 835831
St. Petersburg
Competing Interests:
The authors declare no conflict of interest.
References
1. Moore N, Blin P, Droz C. Pharmacoepidemiology. Handb Exp Pharmacol. 2019;260:433-451. doi: 10.1007/164_2019_318. PMID: 31768750.
2. Montastruc JL, Benevent J, Montastruc F, Bag heri H, Despas F, Lapeyre-Mestre M, Sommet A. What is pharmacoepidemiology? Definition, methods, interest and clinical applications. Therapie. 2019 Apr;74(2):169-174. doi: 10.1016/j.therap.2018.08.001. Epub 2018 Oct 10. PMID: 30389102.
3. Introduction to Drug Utilization Research / WHO International Working Group for Drug Statistics Methodology, WHO Collaborating Centre for Drug Statistics Methodology, WHO Collaborating Centre for Drug Utilization Research and Clinical Pharmacological Services. © World Health Organization 2003. https://www.who.int/publications/i/item/8280820396
4. Rasmussen L, Wettermark B, Steinke D, Pottegård A. Core concepts in pharmacoepidemiology:Measures of drug utilization based on individual-level drug dispensing data. Pharmacoepidemiol Drug Saf. 2022 Oct;31(10):1015-1026. doi: 10.1002/pds.5490. Epub 2022 Aug 11. PMID: 35819240; PMCID: PMC9545237.
5. Hoffmann M, Støvring H. Incidence in pharmacoepidemiology-Basic definitions and types of misclassification. Basic Clin Pharmacol Toxicol. 2022 Jun;130(6):632-643. doi: 10.1111/bcpt.13727. Epub 2022 Apr 13. PMID: 35357769; PMCID: PMC9320840.
6. Caetano PA, Lam JM, Morgan SG. Toward a standard definition and measurement of persistence with drug therapy: Examples from research on statin and antihypertensive utilization. Clin Ther. 2006 Sep;28(9):1411-24; discussion 1410. doi: 10.1016/j.clinthera.2006.09.021. PMID: 17062314.
7. Vrijens B, De Geest S, Hughes DA, Przemyslaw K, Demonceau J, Ruppar T, Dobbels F, Fargher E, Morrison V, Lewek P, Matyjaszczyk M, Mshelia C, Clyne W, Aronson JK, Urquhart J; ABC Project Team. A new taxonomy for describing and defining adherence to medications. Br J Clin Pharmacol. 2012 May;73(5):691-705. doi: 10.1111/j.1365-2125.2012.04167.x. PMID: 22486599; PMCID: PMC3403197.
8. Grégoire J.-P., Moisan, J. Assessment of adherence to drug treatment in database research. In Drug Utilization Research (eds M. Elseviers, B. Wetter-mark, A.B. Almarsdóttir, M. Andersen, R. Benko, M. Bennie, I. Eriksson, B. Godman, J. Krska, E. Poluzzi, K. Taxis, V. Vlahović-Palčevski and R.V. Stichele).https://doi.org/10.1002/9781118949740.ch36
9. Ponté C, Lepelley M, Boucherie Q, Mallaret M, Lapeyre Mestre M, Pradel V, Micallef J. Doctor shopping of opioid analgesics relative to benzodiazepines: A pharmacoepidemiological study among 11.7 million inhabitants in the French countries. Drug Alcohol Depend. 2018 Jun 1;187:88-94. doi: 10.1016/j.drugalcdep.2018.01.036. Epub 2018 Apr 4. PMID: 29649695.
10. Rasmussen L, Pratt N, Hansen MR, Hallas J, Pottegård A. Using the "proportion of patients covered" and the Kaplan-Meier survival analysis to describe treatment persistence. Pharmacoepidemiol Drug Saf. 2018 Aug;27(8):867-871. doi: 10.1002/pds.4582. Epub 2018 Jun 27. PMID: 29952045.
11. Liu X, Kubilis P, Bussing R, Winterstein AG. Development of a refill pattern method to measure polypharmacy in administrative claims databases. Pharmacoepidemiol Drug Saf. 2016 Dec;25(12):1407-1413. doi: 10.1002/pds.4082. Epub 2016 Aug 16. PMID: 27528378.
Review
For citations:
Mukhina S.M., Baranova M.I., Gomon Yu.M. Drug utilization research at the individual level as the main concept of pharmacoepidemiology. Real-World Data & Evidence. 2023;3(2):21-30. (In Russ.) https://doi.org/10.37489/2782-3784-myrwd-33. EDN: FGOIEC
Views:
1833
Email this article 
Post a Comment 